These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27681102)

  • 1. Tumor Static Concentration Curves in Combination Therapy.
    Cardilin T; Almquist J; Jirstrand M; Sostelly A; Amendt C; El Bawab S; Gabrielsson J
    AAPS J; 2017 Mar; 19(2):456-467. PubMed ID: 27681102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft.
    Jia Y; Zhou D; Jia Q; Ying Y; Chen S
    Biomed Pharmacother; 2016 Apr; 79():27-34. PubMed ID: 27044809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Terranova N; Germani M; Del Bene F; Magni P
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice.
    Lee I; Kalota A; Gewirtz AM; Shogen K
    Anticancer Res; 2007; 27(1A):299-307. PubMed ID: 17352247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer.
    Li J; Ye C; Mansmann UR
    Clin Cancer Res; 2016 May; 22(9):2167-76. PubMed ID: 26637276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.
    Bruheim S; Sandvold ML; Mælandsmo GM; Fodstad O
    Anticancer Res; 2013 Sep; 33(9):3615-21. PubMed ID: 24023287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
    Li JY; Ren YP; Yuan Y; Ji SM; Zhou SP; Wang LJ; Mou ZZ; Li L; Lu W; Zhou TY
    Acta Pharmacol Sin; 2016 Jul; 37(7):930-40. PubMed ID: 27180983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
    Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effectiveness of a combined therapy with a new cucurbitacin B derivative and paclitaxel on a human lung cancer xenograft model.
    Marostica LL; de Barros ALB; Oliveira J; Salgado BS; Cassali GD; Leite EA; Cardoso VN; Lang KL; Caro MSB; Durán FJ; Schenkel EP; de Oliveira MC; Simões CMO
    Toxicol Appl Pharmacol; 2017 Aug; 329():272-281. PubMed ID: 28610991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.